Healthcare provider profile · identity verified

Keith Alan Rebehn, MD

Family Practice · RENSSELAER, NY · NPI 1376636910

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	313	79
Omeprazole	Omeprazole	229	71
Atorvastatin Calcium	Atorvastatin Calcium	202	62
Hydrochlorothiazide	Hydrochlorothiazide	184	59
Metoprolol Succinate	Metoprolol Succinate	163	45
Lisinopril	Lisinopril	161	48
Gabapentin	Gabapentin	160	33
Rosuvastatin Calcium	Rosuvastatin Calcium	155	52
Losartan Potassium	Losartan Potassium	138	45
Famotidine	Famotidine	130	49
Amlodipine Besylate	Amlodipine Besylate	123	37
Carvedilol	Carvedilol	123	29
Simvastatin	Simvastatin	122	41
Escitalopram Oxalate	Escitalopram Oxalate	113	28
Ozempic	Semaglutide	107	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	105	32
Metformin Hcl Er	Metformin Hcl	95	26
Albuterol Sulfate Hfa	Albuterol Sulfate	91	34
Pantoprazole Sodium	Pantoprazole Sodium	89	27
Allopurinol	Allopurinol	80	24
Tamsulosin Hcl	Tamsulosin Hcl	77	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	76	18
Eliquis	Apixaban	75	18
Pravastatin Sodium	Pravastatin Sodium	65	21
Zolpidem Tartrate	Zolpidem Tartrate	59	11
Alprazolam	Alprazolam	57	14
Metformin Hcl	Metformin Hcl	54	16
Potassium Chloride	Potassium Chloride	54	14
Sertraline Hcl	Sertraline Hcl	53	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	52	14
Tramadol Hcl	Tramadol Hcl	52	22
Furosemide	Furosemide	50	16
Alendronate Sodium	Alendronate Sodium	49	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	48	15
Finasteride	Finasteride	47	15
Fluticasone Propionate	Fluticasone Propionate	47	15
Citalopram Hbr	Citalopram Hydrobromide	46	11
Ropinirole Hcl	Ropinirole Hcl	45	12
Glimepiride	Glimepiride	43	13
Fluoxetine Hcl	Fluoxetine Hcl	38	11
Lorazepam	Lorazepam	38	suppressed
Synthroid	Levothyroxine Sodium	36	suppressed
Terazosin Hcl	Terazosin Hcl	35	suppressed
Pregabalin	Pregabalin	33	suppressed
Raloxifene Hcl	Raloxifene Hcl	33	suppressed
Januvia	Sitagliptin Phosphate	32	suppressed
Fentanyl	Fentanyl	31	suppressed
Lovastatin	Lovastatin	31	suppressed
Trazodone Hcl	Trazodone Hcl	31	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	31	suppressed
Clopidogrel	Clopidogrel Bisulfate	30	suppressed
Prednisone	Prednisone	30	14
Metoprolol Tartrate	Metoprolol Tartrate	29	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	28	21
Triamcinolone Acetonide	Triamcinolone Acetonide	28	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	27	suppressed
Meloxicam	Meloxicam	27	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	26	15
Ezetimibe	Ezetimibe	25	suppressed
Irbesartan	Irbesartan	25	suppressed
Bupropion Hcl Sr	Bupropion Hcl	24	suppressed
Valacyclovir	Valacyclovir Hcl	24	11
Myrbetriq	Mirabegron	23	suppressed
Propranolol Hcl Er	Propranolol Hcl	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	11
Calcitriol	Calcitriol	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Verapamil Er	Verapamil Hcl	19	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	17	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Bumetanide	Bumetanide	15	suppressed
Clonazepam	Clonazepam	15	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Jardiance	Empagliflozin	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	11
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Silodosin	Silodosin	15	suppressed
Telmisartan	Telmisartan	15	suppressed
Divalproex Sodium Er	Divalproex Sodium	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Desmopressin Acetate	Desmopressin Acetate	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Prolia	Denosumab	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Celecoxib	Celecoxib	12	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	12	suppressed
Colchicine	Colchicine	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Potassium Citrate Er	Potassium Citrate	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Ammonium Lactate	Ammonium Lactate	11	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Nystatin	Nystatin	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Ramipril	Ramipril	11	suppressed
Sildenafil Citrate	Sildenafil Citrate	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error